PFA Pension Forsikringsaktieselskab Invests $1.76 Million in DaVita Inc. $DVA

Key Points

• PFA Pension bought a new stake of 15,482 shares in DaVita in Q4, valued at about $1.76 million, and institutional investors now own roughly 90.12% of the stock.
• Analyst sentiment is mixed with a MarketBeat consensus of "Hold" and a $155.80 target; brokers include UBS (raised target to $190, "buy"), while Zacks cut its rating from strong-buy to hold (overall: 1 Buy, 5 Hold, 1 Sell).
• DaVita beat estimates last quarter (EPS $3.40 vs. $3.24; revenue $3.62B, +9.9% YoY), and the shares trade around $154 with a market cap of about $10.3B and a PE of 15.56.

PFA Pension Forsikringsaktieselskab bought a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 15,482 shares of the company's stock, valued at approximately $1,762,000.

A number of other large investors have also recently made changes to their positions in DVA. Elevation Wealth Partners LLC raised its stake in DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of DaVita during the 2nd quarter worth approximately $43,000. iSAM Funds UK Ltd purchased a new position in shares of DaVita during the 3rd quarter worth approximately $46,000. Stance Capital LLC purchased a new position in DaVita in the 3rd quarter valued at approximately $47,000. Finally, Smartleaf Asset Management LLC increased its stake in DaVita by 34.9% in the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company's stock valued at $59,000 after purchasing an additional 117 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on DVA. UBS Group increased their target price on DaVita from $186.00 to $190.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. TD Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 3rd. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. Zacks Research lowered DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 6th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, DaVita has a consensus rating of "Hold" and a consensus target price of $155.80.

DaVita Trading Up 1.6%

Shares of NYSE DVA opened at $154.15 on Tuesday. The stock has a 50 day simple moving average of $151.18 and a 200-day simple moving average of $131.51. The company has a market cap of $10.30 billion, a PE ratio of 15.56, a P/E/G ratio of 0.53 and a beta of 0.84. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $159.42.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the firm posted $2.24 earnings per share. The business's revenue was up 9.9% on a year-over-year basis. Sell-side analysts forecast that DaVita Inc. will post 14.16 earnings per share for the current fiscal year.

About DaVita

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.